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Sjögren’s syndrome (SS) is a systemic progressive autoimmune disease characterized by a complex pathogenesis
requiring a predisposing genetic background and involving immune cell activation and autoantibody production.
The immune response is directed to the exocrine glands, causing the typical ‘sicca syndrome’, but major organ
involvement is also often seen. The etiology of the disease is unknown. Infections could play a pivotal role:
compared to normal subjects, patients with SS displayed higher titers of anti-Epstein-Barr virus (EBV) early
antigens, but lower titers of other infectious agent antibodies such as rubella and cytomegalovirus (CMV) suggest
that some infections may have a protective role against the development of autoimmune disease. Recent
findings seem to show that low vitamin D levels in patients with SS could be associated with severe
complications such as lymphoma and peripheral neuropathy. This could open new insights into the disease
etiology. The current treatments for SS range from symptomatic therapies to systemic immunosuppressive drugs,
especially B cell-targeted drugs in cases of organ involvement. Vitamin D supplementation may be an additional
tool for optimization of SS treatment.
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Sjögren syndrome (SS) is a chronic autoimmune inflam-
matory disease that primarily involves the exocrine glands,
resulting in their functional impairment. The syndrome
can present either alone (primary Sjögren’s syndrome
(pSS)) or in the context of an underlying connective tissue
disease, most commonly rheumatoid arthritis (RA) or sys-
temic lupus erythematosus (SLE) (secondary Sjögren’s syn-
drome (sSS)) [1].
SS is the second most common autoimmune rheumatic
disease, with an estimated prevalence ranging from 0.1 to
4.8% in different studies. It mainly affects middle-aged
women, with a female to male ratio reaching 9:1 [2].
Although the etiology of SS remains unknown, suscep-
tibility to the disease can be ascribed to the interplay* Correspondence: tincani@med.unibs.it
1Rheumatology and Clinical Immunology Unit, Spedali Civili, Piazzale Spedali
Civili 1, 25100 Brescia, Italy
2Chair of Rheumatology, Department of Clinical and Experimental Sciences,
University of Brescia, Spedali Civili, Piazzale Spedali Civili 1, 25100 Brescia
Italy
Full list of author information is available at the end of the article
© 2013 Tincani et al.; licensee BioMed Central
Commons Attribution License (http://creativec
reproduction in any medium, provided the orbetween genetic, environmental and hormonal factors.
The chronic immune system stimulation is thought to
play a central role in the pathogenesis of the disorder, as
illustrated by several indices of immunological hyper-
activity, including various autoantibodies, in particular
anti-Ro/SS-A (anti-Ro) and anti-La/SS-B (anti-La) [1].
A genetic predisposition to SS has been suggested [3].
Familial clustering of different autoimmune diseases and
coassociation of multiple autoimmune diseases in individ-
uals have both frequently been reported. It is common for
a SS patient to have relatives with other autoimmune dis-
eases (30%) [1]. The polymorphic major histocompatibility
complex (MHC) genes are the best documented genetic
risk factors for the development of autoimmune diseases;
with regard to SS, DRB1*0301-DQB1*0201-DQA1*0501
haplotypes are the strongest risk factors for the formation
of an anti-Ro/La response and to the development of the
disease [4].
Although many human leukocyte antigen (HLA) hap-
lotypes have been found in SS subjects from different
ethnic boundaries, the majority of patients with SS carry
a common allele, DQA1*0501, probably involved inLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cant different geographic distribution has been described
in pSS to date [6].
In the current review we present the complexity of SS
from different points of view, reporting on the current
cutting edge of knowledge about this disease. This
multidisciplinary approach to SS is the result of a sym-
posium held in Brescia (Italy) in June 2012, involving
several specialists who take care of different aspects of
the diagnosis, management and therapy of SS.
Clinical features and classification
SS typically presents as dry eyes (xerophthalmia or kerato-
conjunctivitis sicca (KCS)) and dry mouth (xerostomia)
[7]. KCS usually presents insidiously over a period of sev-
eral years. Affected patients may describe a ‘gritty’ or
‘sandy’ feeling in their eyes [8]. Complications of xero-
phthalmia include corneal ulceration and infection of the
eyelids. Dryness of the mouth may give rise to difficulties
in the swallowing of dry foods without fluid, and need for
frequent small sips of water, also at night. Loss of the pro-
tective and antimicrobial properties of saliva may increase
dental caries and predispose patients to oral candidiasis.
Parotid swelling and other xeroses, such as dryness of the
nose, throat, skin, and vagina, also often occur [8].
Establishing the diagnosis of SS is often difficult. The
symptoms are non-specific: sicca symptoms are ex-
tremely common, especially in older patients, partly due
to age-related atrophy of secreting tissues and partly due
to other conditions, especially use of drugs.
No single laboratory test allows for definitive diagnosis
of SS. However, a combination of abnormal test results
is frequently observed: elevated erythrocyte sedimenta-
tion rate (ESR), mild normochromic normocytic anemia,
leukopenia and polyclonal hypergammaglobulinemia.
Autoantibodies are present in the majority of SS cases:
rheumatoid factor (RF), Anti-nuclear antibodies (ANA)
and anti-Ro and anti-La are strongly indicative of SS, al-
though not exclusive [8].
There is no single disease-specific diagnostic criterion
for SS. The most widely used classification criteria are
those revised in 2002 by a joint effort by research groups
in Europe and in the USA (American-European Consen-
sus Group (AECG)) (Table 1) [9,10]. In addition to the
subjective symptoms of dry eyes and dry mouth, the fol-
lowing objective signs should be present: ocular signs
by Schirmer’s I test and/or Rose Bengal score; focal
sialadenitis by histopathology; salivary gland involvement
by salivary scintigraphy, parotid sialography or unstimu-
lated salivary flow; and autoantibodies of anti-Ro and/or
anti-La specificity. The diagnostic role of the histopath-
ology of minor salivary glands has been considered im-
portant and is currently considered as a ‘gold standard’,
although a recent meta-analysis has shown that thediagnostic usefulness has actually only been evaluated in
a few studies [11].
Recently, the Sjögren’s International Collaborative Clin-
ical Alliance (SICCA) proposed a new expert consensus
approach consisting of classification criteria based entirely
on objective measures [12]. In particular, not only have
ocular and oral symptoms have been deleted, but also the
study of salivary gland involvement has been excluded
from the criteria (Table 1).
In fact, the evaluation of salivary gland involvement in
SS is still a matter of debate. In addition to standard
tests for assessment of salivary gland involvement, namely
the unstimulated salivary flow test, salivary gland scintig-
raphy and contrast sialography, other methods have been
studied such as magnetic resonance sialography and ultra-
sonography (US) [14]. It has been suggested that US may
provide useful diagnostic information comparable to that
of biopsy of the minor salivary glands, but US is less ex-
pensive and non-invasive [15,16].
Differential diagnosis of ‘dry eye’
The importance of objective tests for the definition of
ocular dryness has been stressed by the 2012 criteria
[12]. Therefore, correct evaluation of a ‘dry eye’ becomes
critical in the investigation of patients with a suspected
case of SS.
Dry eye syndrome is a common but very complex dis-
order of the tear film. Over the last few decades substan-
tial progress has been made in understanding the
structural elements of the tear film and ocular surface
leading ultimately to revised concepts about the way in
which the tear film is formed and maintained, and the
pathophysiologic events operative in the development of
dry eye.
The structure of tear film can be subdivided into an
anterior lipid layer, a middle aqueous layer and an inner-
most mucin layer. Meibomian glands, lacrimal glands,
goblet cells and epithelial cells of the ocular surface pro-
duce these layers. In the 1980s, for the first time, re-
searchers started to consider that the ocular surface is a
functional unit (lacrimal functional unit (LFU)), and its
components are represented by the lacrimal gland, cor-
neal epithelium, conjunctival epithelium and goblet cells,
tear film and the eyelid border with Meibomian glands
[17]. The ocular surface is essential for visual function
and is considered as an interface between the external
environment and the host. Hydrodynamic factors, such
as eyelid blinking and closure, are essential to maintain
ocular surface functionality. In 1995, the Dry Eye Study
Group [18] described ‘dry eye syndrome’ as a tear film
pathology that occurs due to either decreased tear pro-
duction or increased evaporation. It causes damage
to the interpalpebral ocular surface and is associated
with a variety of symptoms reflecting ocular discomfort
Table 1 Comparisons between the 2002 and 2012 criteria for Sjögren’s syndrome (SS)
2002 criteria from the American-European Consensus
Group (AECG) (Vitali et al. [9])
2012 criteria from the Sjögren’s International Collaborative
Clinical Alliance (SICCA) (Shiboski et al. [12])
(I) Ocular symptoms (positive response to at least one of three): (I) Ocular symptoms:
Daily, persistent, troublesome eyes for more than 3 months Not included
Recurrent sensation of sand or gravel in the eyes
Use of tear substitutes more than three times per day
(II) Oral symptoms (positive response to at least one of three): (II) Oral symptoms:
Daily feeling of dry mouth for more than 3 months Not included
Recurrently or persistently swollen salivary glands as an adult
Frequent drinking of liquids to aid in swallowing food
(III) Ocular signs (positive result for at least one of two tests): (III) Ocular signs:
Schirmer’s test, performed without anesthesia (≤5 mm in 5 minutes) Keratoconjunctivitis sicca with ocular staining score ≥3, according to
Whitcher et al. [13] (preferential use of fluorescein staining or lissamine
green staining, but break-up time; and unanesthetized Schirmer’s test can
also be used). It is assumed that individual is not currently using daily eye
drops for glaucoma and has not had corneal surgery or cosmetic eyelid
surgery in the last 5 years).
Rose Bengal score or other ocular dye score (≤4 according to van
Bijsterveld’s scoring system)
(IV) Histopathology in minor salivary gland biopsy: (IV) Histopathology in minor salivary gland biopsy:
Focal lymphocytic sialoadenitis, with focus score ≥1 (a focus is defined
as ≥50 lymphocytes per 4 mm2 of glandular tissue adjacent to normal
appearing mucous acini)
Focal lymphocytic sialadenitis, with a focus score ≥1 (a focus is defined
as ≥50 lymphocytes per 4 mm2 of glandular tissue adjacent to normal
appearing mucous acini)
(V) Salivary gland involvement (positive result for at least one of three): (V) Salivary gland involvement:
Unstimulated whole salivary flow (≤1.5 ml/15 minutes) Not included
Parotid sialography showing the presence of diffuse sialectasis
(punctuate, cavitary or destructive pattern), without evidence of
obstruction in the major ducts
Salivary scintigraphy showing delayed uptake, reduced concentration
and/or delayed excretion of tracer
(VI) Autoantibodies: (VI) Autoantibodies:
Presence in the serum of antibodies to Ro (SS-A) or La (SS-B) antigens,
or both
Positive serum anti-SS-A/Ro and/or anti-SS-B/La or (positive rheumatoid
factor and anti-nuclear antibody (ANA) titer ≥1:320)
Classification criteria: Classification criteria:
Primary SS: At least two of the three items in order to classify a patient as SS
The presence of any four of the six items, as long as either item IV
(histopathology) or item VI (serology) is positive
The presence of any three of the four objective criteria (items III, IV,
V and VI)
Secondary SS:
In the presence of another connective tissue disease, the presence of
item I or item II, plus any two from items III, IV and V
Exclusion criteria: Exclusion criteria:
Past head and neck radiation treatment, hepatitis C infection, AIDS,
pre-existing lymphoma, sarcoidosis, graft versus host disease, use of
anticholinergic drugs (since a time shorter than fourfold the half-life
of the drug)
History of head and neck radiation treatment, hepatitis C infection, AIDS,
sarcoidosis, amyloidosis, graft versus host disease, IgG4-related disease
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ition of ‘dry eye syndrome’. However, the international
report of the Dry Eye Workshop (DEWS) changed the
definition of dry eye in 2007 [19]. According to DEWS,
‘dry eye syndrome’ is a multifactorial disease of the tearsand ocular surface that results in symptoms of discom-
fort, visual disturbance, and tear film instability with
potential damage to the ocular surface itself. It is accom-
panied by increased osmolarity of the tear film and in-
flammation of the ocular surface. The tear film is a very
Figure 1 Severe ocular surface damage in a dry eye patient.
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system, which promptly responds to pathological events
with modifications of quantity and quality of tear pro-
duction, an increase in proliferation and migration of
epithelial cells and permeability of conjunctival vessels.
Another crucial component of the system is the neural
network. Sensory receptors monitor conditions of the
tears and cells, sending afferent signals to the central
nervous system that, in turn, send efferent impulses
mainly to the secretory glands and cells, effecting
changes in composition and volume to maintain homeo-
stasis and to respond to injury and stress. As stated be-
fore, dry eye is a multifactorial disorder of the LFU; it
involves several interacting mechanisms. Dysfunction of
any component can lead to dry eye disease by causing
alterations in the volume, composition, distribution, sta-
bility and clearance of the tear film. A key role is played
by decreased tear production and epithelial damage
along with tear hyperosmolarity and tear film instability.
Altogether these events start self-perpetuating and mu-
tually reinforcing complex global mechanisms, ultim-
ately leading to ocular surface inflammation [20]. The
latter, regardless of the initiating event, is a key factor
perpetuating dry eye.
According to the DEWS report, dry eye disease com-
prises two major etiopathogenic groups: evaporative dry
eye and aqueous tear-deficient dry eye (Figure 2).
Hyperevaporative dry eye can be due to intrinsic and ex-
trinsic causes. Among the first group are changes in tear
composition, eyelid disorders, incomplete blinking or re-
duced blinking rate, ocular surface irregularities and
drug action. Extrinsic causes include, among others, vita-
min A deficiency, topical drug preservatives, contact lens
wear and ocular surface disease. Aqueous tear deficient
dry eye can be subdivided into SS and non-SS syndrome
dry eye groups. The latter group has several primary
causes, including the lack of a lacrimal gland (congenitalor acquired), impairment or dysfunction of the lacrimal
gland, reflex block and drug action. Non-SS dry eye can
also be secondary to a variety of conditions. SS dry eye
is associated with autoimmune inflammation in the lac-
rimal glands [19].
It should be remembered, however, that instances of
hyperevaporative and aqueous tear deficient dry eye in
most cases are not clinically so well defined and often
there is a certain degree of overlap between these two
dry eye groups. A hyperevaporative dry eye over time
also becomes aqueous tear deficient, and vice versa,
making it difficult to precisely classify the condition.
Ophthalmologists should recognize and diagnose dry
eye syndrome to prevent or treat ocular surface patholo-
gies. As it may be associated with a variety of causes, it
is important to perform a comprehensive evaluation.
This should include a complete clinical history, accurate
examination of the patient (skin, blinking rate, eye and
lid morphology, and so on), a slit-lamp examination and
laboratory tests that can help towards a diagnosis of dry
eye related to SS. Lacking a single conclusive test to
diagnose dry eye syndrome, a lot of different procedures,
easy or complicated, cheap or expensive and more or
less useful, have been developed in order to help oph-
thalmologists. The tests of choice to diagnose dry eye in-
clude break-up time (BUT), ocular surface staining and
Schirmer’s test [12]. The reasons for their use lay in their
reproducibility, sensitivity and in the fact that all of them
are quite easy to perform. Ocular surface dyes used in
clinical practice are fluorescein and lissamine green
(Figure 3). Rose Bengal was progressively abandoned be-
cause of patient discomfort. The lissamine green dye test
is very sensitive and stains damaged epithelial cells with-
out causing any discomfort to patients.
Once a diagnosis is confirmed, management of dry eye
depends on the cause and severity of the condition. New
treatment approaches are designed to modify the under-
lying disease process. Every associated condition must be
treated. Therapy should normalize the tear film, de-
crease ocular surface inflammation, stimulate epithelial
healing, improve neural feedback, decrease lacrimal
gland inflammation and improve its function.
In conclusion, therapy should be aimed at protecting
the ocular surface, alleviating the signs and symptoms of
dry eye and, most importantly, at breaking the vicious
cycle leading to chronic inflammation, thus improving
the quality of life of patients.
Not only ‘sicca syndrome’: extraglandular manifestations
of SS
Despite glandular involvement being the major and typ-
ical feature of pSS, this autoimmune disease can have
several systemic manifestations. In fact, 30% to 70% of
patients develop systemic involvement before or after
Figure 2 Dry eye classification flow chart (Dry Eye Workshop Report, 2007) [19]. The causes of ‘dry eye syndrome’ are subdivided into
aqueous-deficient and evaporative groupings. Sjögren’s syndrome (SS) belongs to the first group. Modified from [19].
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sidered that this group of patients more commonly has
circulating anti-Ro and anti-La autoantibodies, in com-
parison with the group of patients with sicca-limited
disease [25].Figure 3 Lissamine green staining of the conjunctiva in dry
eye syndrome.Most extraglandular manifestations, similar to the exo-
crine gland involvement, can be considered as expres-
sion of the so-called ‘autoimmune epithelitis’ because
the primary target of the autoimmune response is the
epithelial component [26,27]. Nevertheless, in other clin-
ical manifestations the pathogenesis seems to be com-
pletely different as it may involve vasculitis and/or
immune complex deposition and complement activation,
as is the case in skin vasculitis, glomerulonephritis and
peripheral neuropathy.
One of the most frequent symptoms in pSS is repre-
sented by fatigue, prominent in approximately 70% of
patients. Though the instruments for fatigue assessment
are still inadequate or lacking, it seems that the physical
and somatic rather than mental aspects of fatigue are
more severely and frequently affected in pSS [28]. A
moderate correlation between depression and fatigue
has also been found. One possible explanation is that fa-
tigue and depression share common underlying bio-
logical mechanisms.
Respiratory manifestations are frequently detected but
they are clinically significant in only 10% of patients [29].
The more common clinical symptoms are represented by
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dyspnea. They are caused by dry nose, dry trachea, small
airway obstruction and/or interstitial lung disease (ILD).
Non-specific interstitial pneumonia (NSIP) seems to be
the most frequent histological pattern of ILD but lympho-
cytic IP (LIP) and usual IP (UIP) are also present.
The kidneys are often involved in pSS. The major clin-
icopathological entity is interstitial nephritis (IN), which
appears early or even may precede the onset of sicca
symptoms [30]. Distal renal acidosis (both type I and II)
is the most frequent clinical presentation. Aside from
IN, glomerulonephritis (GMN) is more rarely detected
in patients with pSS and is strongly associated with low
C4 levels and mixed cryoglobulinemia. However, IN is
frequently subclinical and overt clinical renal disease is
detectable in approximately 5% of patients with pSS, in
which IN and GMN are almost equally distributed.
With regard to skin involvement, nearly half of all pa-
tients with pSS may present cutaneous manifestations
consisting of skin xerosis, angular cheilitis, erythema
anulare, chilblain lupus and skin vasculitis that includes
flat or palpable purpura and urticarial vasculitis [31].
Arthralgias are commonly reported in patients with
pSS while typical non-erosive arthritis is less frequent
[32]. Likewise, myalgias are frequent while myositis is
rarely diagnosed in pSS.
Gastrointestinal manifestations include nausea, dys-
phagia or epigastric pains that are frequently due to dry-
ness of the pharynx and esophagus or to esophageal
dysmotility and gastritis. The typical histological pattern
is chronic atrophic gastritis with lymphoid infiltration.
Hyperamylasemia is rather frequent, though very rarely
it is an expression of acute or chronic pancreatitis. Ab-
normal liver tests are not uncommon but autoimmune
hepatitis is diagnosed in 1.7% to 4% of patients with pSS,
while autoimmune cholangitis (with histological changes
similar to stage I primary biliary cirrhosis) develops mainly
within the 5% to 10% of patients with antimitochondrial
antibodies [33].
Approximately 20% of patients with pSS develop auto-
immune thyroiditis (primarily Hashimoto thyroiditis and
to a lesser extent, Graves’ disease) and more than 50%
of them have subclinical hypothyroidism. Autoantibodies
against thyroid peroxidase (anti-TPO) and thyroglobulin
(anti-TG) can be used as primary indicators of patients
who are prone to developing thyroid disease in the fu-
ture [34].
The prevalence of neurological manifestations in pSS
varies between 2% to 60% with pure or predominantly sen-
sory polyneuropathies being the most common manifesta-
tions (for example, sensory ataxic or small fiber sensory
painful neuropathy) [21,35]. Sensorimotor polyneuropathy
and polyradiculopathy, mononeuritis multiplex, autonomic
neuropathy (for example, Adie’s pupils and orthostatichypotension), trigeminal and other cranial neuropathies
are other manifestations of the involvement of peripheral
nervous system (PNS) in pSS. Central nervous system in-
volvement is much less common than PNS involvement,
with multiple sclerosis-like changes, seizures, transverse
myelitis, aseptic meningitis, optic neuritis, diffuse enceph-
alopathy and dementia as reported manifestations [36].
Pathogenesis, histopathology and progression to
lymphoma
The pathological hallmark of SS is a chronic inflammatory
infiltrate in the exocrine glands, mainly constituted by ac-
tivated T and B cells [37,38]. The immune-mediated dam-
age appears in the apoptosis of glandular epithelial cells
[39] and seems to be mediated by several proinflammatory
T helper 1-type cytokines [40]. The epithelial cells of saliv-
ary glands from patients with SS also display alterations in
cell adhesion and shape [41]. The immune dysregulation
seems to be orchestrated by genetic factors, including cer-
tain HLA phenotypes and polymorphisms in genes encod-
ing cytokines or factors implicated in cytokine signaling,
by the environment (such as viruses) and by the hormonal
milieu [42].
The histopathological picture of SS is the chronic
periductal sialoadenitis [43]. In the early stages of dis-
ease, focal aggregates of lymphocytes appear in the glan-
dular lobules. Initially, the lymphocytes infiltrate the
space around small interlobular-intralobular ducts, and
subsequently they determine the atrophic involution of
the acina. The lymphocyte infiltrate then spreads from
the periductal position to the parenchyma, with the final
result of a diffuse infiltration of lymphocytes and loss of tis-
sue architecture. In addition, the lymphocytes initiate the
damage to the ducts with the formation of epimyoepithelial
lesions. As a result, hyaline material, similar to a basal
membrane, is present in the lumen of the ducts. Of
note, some morphological alterations described in SS
(‘epimyoepithelial sialoadenitis’) can also be found in
the absence of overt disease (no clinical and serological
features of SS). Such a histopathological picture can be
defined as a ‘benign lymphoepithelial lesion’.
According to the international guidelines [9,12], the
histological criteria for the definition of SS are both quali-
tative and quantitative: the ‘focus’ must be composed of at
least 50 lymphocytes infiltrating the periductal area; 1
focus must be detected in a tissue area of at least 4 mm2
(see Figure 4).
The main complication of SS is hematological neopla-
sia. Compared to healthy individuals, patients with SS
have a 10 to 50 times higher risk of lymphoma and,
according to a large case series, 2% to 9% of patients
with SS develop lymphoma [7].
The parotid gland is affected in the majority of cases
and the most frequent type of non-Hodgkin’s (NH)
Periductal lymphoid foci 
Figure 4 Microscopy of a minor salivary gland in Sjögren’s
syndrome (SS): ‘periductal lymphoid focus’. The finding of at
least 1 focus (periductal aggregate of at least 50 lymphocytes,
mostly CD4+) in 4 mm2 of tissue is diagnostic for SS. The ‘score’ is




infiltrated by  
lymphoma 
Figure 6 Anti-CD20 staining of non-Hodgkin’s (NH) marginal B
cell lymphoma. The lymphoid infiltrate is constituted by medium-
sized cells, with a cleaved nucleus and a large cytoplasm, which are
factors strongly positive for CD20.
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associated lymphoid tissue (MALT). Such lymphomas can
also be found in other organs (stomach, lungs and kidney).
Other types of lymphoma are rare in SS: Hodgkin’s lymph-
oma, B cell NH lymphoma with diffuse giant cells and
centrofollicular histotypes and T cell NH lymphoma [44].
Despite the inflammatory infiltrate in the salivary
glands being mostly made up of T cells, the development
of lymphoma involves the B cells. The lymphoma cells
in the marginal zone NH type are medium-sized cells
with a cleaved nucleus and large cytoplasm (Figure 5)
and with a positive CD20 reaction (Figure 6). Such cells
cluster in the epimyoepithelial islets. Initially, there
might be several different clones of B cells, but over timeLymphoma-free  
parenchima 
Parenchima  
infiltrated by  
lymphoma 
Figure 5 Microscopy of non-Hodgkin’s (NH) marginal B cell
lymphoma. The most frequent lymphoma in Sjögren’s syndrome
(SS) is the NH marginal B cell type, which comes from mucosa-
associated lymphoid tissue (MALT).a single clone can progressively expand and invade the
glandular parenchyma with the formation of a lymphoma.
Risk factors for the development of lymphoma have
been identified in patients with SS and include the pres-
ence of palpable purpura, low C4 and mixed monoclonal
cryoglobulinemia. Patients displaying these risk factors
should be monitored closely [44].Serological profile
SS is an autoimmune disease characterized by a strong
polyclonal B cell activation and different circulating
autoantibodies, classically represented by anti-nuclear
antibodies, anti-Ro, anti-La, rheumatoid factor and,
more rarely, anti-centromere, anti-Ki/SL, anti-Ku or
anti-p80 coilin.
Other autoantibodies have been described in SS, probably
involved in the pathogenesis of different aspect of the dis-
ease, such as anti-α fodrin [45], anti-carbonic anhydrase,
and anti-muscarinic receptor antibodies [46].
Anti-Ro and anti-La antibodies are considered the
classical hallmark of SS, detected in about 60% and
40% of SS, respectively, and included in both the AECG
and SICCA classification criteria [9,12]. Anti-Ro and
anti-La antibodies define a disease with a higher rate
of extraglandular manifestations and more active
immunological status, when compared with ‘seronega-
tive’ SS cases (without anti-Ro or anti-La antibodies).
Anti-Ro/La-positive patients with SS can show severe
hypergammaglobulinemia, cryoglobulins and a high
risk of developing lymphoma [47].
Circulating levels of anti-Ro/La do not correlate with
disease activity; regardless, the IgA anti-Ro titer seems
to be associated with the rate of lymphocyte glandular
infiltration. In addition, the expression of La and 60 kDa
Ro antigens in ductal glandular cells could represent a
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tion and tissue-specific immune response. Moreover, a
strong correlation was found between circulating auto-
antibodies and Ro/La producing cells in salivary glands
[48]. Anti-Ro and anti-La autoantibodies from SS sera,
but not healthy IgG, can activate caspase 3 and deter-
mine apoptosis in human salivary gland cells, in vitro
[49]. In addition, anti-Ro/SS-A antibodies stimulate the
production of proinflammatory cytokines interleukin
(IL)-6 and IL-8 by human healthy salivary gland epithe-
lial cells [50]. Therefore, these autoantibodies seem to
have a pathogenic role for the impairment of the
secretory function in the salivary glands.
Anti-Ro antibodies recognize a macromolecular com-
plex, constituted by 60 kDa and 52 kDa Ro proteins and
short cytoplasmic RNA molecules. The 60 kDa and
52 kDa Ro antigens are encoded by different genes and
are completely different in amino-acid sequence, epitopes
and biological role within the cell. The 60 kDa Ro is dir-
ectly bound to RNA of the Ro complex and seems to have
a role in DNA replication. By contrast, 52 kDa Ro does
not contain an RNA-binding sequence but could be con-
sidered part of the ‘Ro protein’ through the link with
60 kDa Ro: it seems to have a role in ubiquitination and
modulation of innate immune system though regulation
of proinflammatory cytokines and interferon related fac-
tors. Anti-Ro antibodies recognize isolated 60 kDa Ro
(which contains only conformational epitopes) or 60 kDa
Ro associated with 52 kDa Ro (which has only linear epi-
topes). Isolated anti-52 kDa Ro antibodies can be found in
SS, but they can also be frequently detected in other auto-
immune disorders [51,52]. Interest has been raised for
anti-52 kDa Ro, as there are new insights on the mecha-
nisms of intracellular immunity mediated by these auto-
antibodies when they penetrate into cells [53].
Almost every assay can accurately detect anti-La anti-
bodies. By contrast, the correct assays for anti-Ro anti-
bodies should use raw or conformational antigens in order
to detect autoantigens with the best sensitivity and specifi-
city. Counterimmunoelectrophoresis, using raw spleen ex-
tracts, shows a similar performance level to the ‘gold
standard’ immunoprecipitation assay. Western blotting
tests, ELISAs and multiplex microbead immunoassays
show variable results depending on antigen purification,
synthesis and maintenance of conformational epitopes of
Ro peptides [54].
Other autoantibodies can be detected in SS, as associ-
ated or substitutes of anti-Ro antibodies [46]. Anti-
centromere antibodies (ACA), usually found in limited
systemic sclerosis (SSc), are detected in 5% to 10% of SS
cases as an alternative to anti-Ro/La antibodies. ACA-
positive SS shows SSc features, such as Raynaud’s
phenomenon, puffy hands, dysphagia and teleangectasia,
but has a lower rate of pulmonary involvement comparedto ACA + SSc. These patients show sicca symptoms not
due to glandular fibrosis, as observed in SSc, but due to a
high rate of lymphocyte infiltration as well as anti-Ro/La-
positive SS. These data suggest that ACA-positive SS
could be considered an overlap SS/SSc disease [55].
Anti-Ki/SL, anti-Ku and anti-p80 coilin antibodies are
more rarely found in SS. Anti-Ki/SL antibodies, originally
found in SLE with sicca, have been described in primary
SS in association with anti-Ro or as isolated markers [56].
Anti-p80 coilin has been detected in SS or SSc, especially
when associated with primary biliary cirrhosis [57]. More-
over, anti-Ku antibodies are usually considered markers of
overlap SSc-myositis or SSc/SLE syndrome [58]. They
have been detected in SS with features of SSc, cutaneous
lupus and/or myositis.
In summary, most patients with SS show a mild dis-
ease with a simple autoantibody profile. Regardless, anti-
Ro and La antibodies likely play a pathogenic role in
inducing local inflammation and damage and are sero-
logical markers of systemic complications. Other auto-
antibodies, such as ACA and anti-Ku, may define a
more complex disease with overlap features and differ-
ent prognosis.
Association of SS with other autoimmune diseases
SS may occur in isolation, often referred to as primary
SS, or in conjunction with another connective tissue dis-
ease, most commonly RA or SLE [59]. This association
is termed secondary SS, according to the AECG, even if
SS was diagnosed as secondary disease many years be-
fore the primary disease [9].
SS has been described in association with a large variety
of both organ-specific and systemic autoimmune diseases.
In a series of 114 patients with pSS [60], a range of 13
associated autoimmune diseases was detected. In all, 38
patients (33%) were diagnosed as having 1 additional auto-
immune disease, 7 (6%) had 2, and 2 (2%) had 3. The most
common autoimmune disorder was hypothyroidism
(14%). Similarly, a more recent cohort of 410 patients with
SS [61] showed the presence of polyautoimmunity in 134
(32.6%), with thyroid disease being the most common
(21.5%). The prevalence of systemic diseases such as RA
and SLE was around 8%. As the presence of a concomitant
autoimmune disease involves nearly one-third of patients
with SS, a common pathogenic background may be advo-
cated and the search for polyautoimmunity is warranted
in every SS patient.
The relationship between SS and SLE has been re-
cently addressed in a meta-analysis [62]. In a total of
2489 SLE patients, the estimated prevalence of SS was
17.8%. The clinical features of SLE-SS patients were
found to be: (i) older age, (ii) increased frequency of oral
ulcers and arthritis and (iii) proteinuria and CNS in-
volvement, though these tended to be less frequent.
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DNA antibodies were equally present in both groups,
while anti-Ro and anti-La were more frequent, and anti-
Sm and anti-cardiolipin antibodies were less prevalent in
SLE-SS than SLE alone. Overall, the combined disease
SLE-SS seems to be characterized by less organ involve-
ment, a more specific autoantibody profile and a favor-
able clinical outcome.
The evolution towards SLE in patients with pSS has also
been addressed. In a cohort of 100 patients with pSS, 15%
of them could be classified as having SLE after a follow-up
period of 10 years. Patients who developed SLE had a
lower age, lower C3 concentration, higher level of IgG,
and the presence of anti-La at the time of diagnosis of pSS
[63]. In a larger cohort of 445 patients with pSS, the devel-
opment of SLE was observed in only 1.3% of the patients,
after a mean period of 77 months [64].
RA is frequently associated with both sicca symptoms
and true sSS. In a Spanish cohort of RA patients, a cumu-
lative prevalence of sSS was described in 17% of the pa-
tients at a disease duration of 10 years [65]. In a cohort in
Austria the reported prevalence of sSS was 22% [66].
In a Greek cohort, RA patients with high titers of RF
were reported to be more likely to have sSS [67]. In
Finland, a doubled standardized incidence ratio for NH
lymphoma in RA patients with sSS when compared with
RA patients without SS was described [68].
Sicca syndrome is also common among patients with
SSc due to fibrotic changes of the salivary glands. In ori-
ginal cohorts of SSc patients the prevalence of sSS was
reported to be 17% and 29% [69,70].
In 2 more recent studies involving 133 patients with
SSc and sicca syndrome (14% classified as sSS) [71] and
27 patients with SSc + sSS compared with 202 SSc pa-
tients without sSS [72], it was found that SS associated
with SSc was more often complicated by peripheral
neuropathy and additional autoimmune disease or auto-
antibodies, not typical for either pSS or SSc. It was sug-
gested that SS may be protective against systemic
sclerosis-associated pulmonary fibrosis. Limited SSc was
predominantly associated with SS in these studies (81%
and 95%, respectively).
There have been no studies to date of patients with
mixed connective tissue disease (MCTD) that report the
prevalence of SS. The development of MCTD in pSS has
not been described so far [60,64]. The prevalence of
anti-ribonucleoprotein autoantibodies (anti-RNP) in the
absence of coexisting MCTD has been reported in 4% of
patients with pSS [55].
Novel aspects of SS: the role of infections and vitamin D
Infections and SS
The etiology of autoimmune diseases (AID) is multifactorial
where genetic, immunologic, hormonal and environmentalfactors play in concert in their induction. The final step de-
termining the date of emergence of an AID is most prob-
ably an environmental trigger, which is generally of
infectious origin [73]. In the interplay between infectious
agents and autoimmunity it was found that the same infec-
tious agent (that is, Epstein-Barr Virus (EBV)) may be in-
volved in inducing many autoimmune diseases, while the
same autoimmune disease may be caused by various agents
(that is, EBV, cytomegalovirus (CMV), Helicobacter pylori,
and so on) [74].
Recently, several multicenter studies analyzed a large
number of sera samples (>2,500) from patients with
AID such as SS, SLE, antiphospholipid syndrome
(APS), RA, vasculitides, and others for the presence of
a profile of anti-infectious agents antibodies including
EBV, CMV, H. pylori, rubella, treponema, Herpes virus
and toxoplasmosis. In several diseases a higher preva-
lence and titers of anti-infectious antibodies were found
compared with healthy controls matched for sex, age
and ethnicity [75-80]. For instance, in patients with SS
the prevalence and titers of antibodies against EBV-
early antigen were significantly higher than in their
control group (P = 0.0003).
Interestingly, in some diseases lower titers of anti-
infectious agents were found, such as the lower prevalence
and titers of rubella and CMV antibodies (IgM) detected
in patients with SS compared to controls (P <0.02). This
may allude indirectly to the notion that some infectious
agents may have a protective rather than a pathogenic role
for a specific autoimmune disease.
Furthermore, a certain infectious agent may determine
why an individual with the ‘proper’ genetic background
will develop one AID rather than others, as well as its
clinical manifestations and severity.
Low levels of vitamin D are associated with neuropathy
and lymphoma among patients with SS
The morbidity of SS is mainly determined by extraglandular
disease and increased prevalence of lymphoma. Environ-
mental and hormonal factors, such as vitamin D, may play
a role in the pathogenic process and disease expression.
The levels of vitamin D and their association with
manifestations of SS were studied in a large international
multicenter cohort [81]. Vitamin D levels were deter-
mined in 176 patients with pSS and 163 matched healthy
volunteers utilizing LIAISON chemiluminescent immu-
noassays (DiaSorin, Saluggia, Italy). Mean vitamin D
levels were comparable between patients with SS and
controls: 21.2 ± 9.4 ng/ml and 22.4 ± 10 ng/ml, respect-
ively. Peripheral neuropathy was diagnosed in 23% of pa-
tients with SS and associated with lower vitamin D
levels (18.6 ± 5.5 ng/ml vs 22.6 ± 8 ng/ml (P = 0.04)).
Lymphoma was diagnosed in 4.3% of patients with SS,
who had lower levels of vitamin D, 13.2 ± 6.25 ng/ml,
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8 ng/ml; P = 0.03). Other clinical and serological mani-
festations did not correlate with vitamin D status.
This study reported for the first time the presence of
low vitamin D levels in patients with pSS with peripheral
neuropathy. Overall, it seems that vitamin D deficiency
may be a component in the pathogenesis of neuropathy
in pSS, and may be used for monitoring and treatment
of this condition [82-87].
Patients with pSS are at increased risk for NH lymph-
oma compared to healthy populations [44]. While the
relationship between vitamin D and the risk for lymph-
oma in pSS has not been reported previously, there is
some evidence from case–control studies that low diet-
ary intake of vitamin D is associated with an increased
risk for NHL in the normal population [88,89]. Vitamin
D and its metabolites have been shown to have an
antiproliferative effect on lymphoma cell lines and to at-
tenuate their vitamin D receptor (VDR) expression [90].
Thus, low vitamin D levels may join low comple-
ments components and the presence of cryoglobulins
in predicting eventual development of lymphoma in pa-
tients with SS.
Given the associations between hypovitaminosis D and
severe complications of SS, it can be proposed that vita-
min D supplementation should be given to every patient
with SS.
Sjögren’s syndrome: a female disease
Interestingly, it has also recently been claimed that vita-
min D may be linked with a severe complication that
may affect pregnant women with anti-Ro and anti-La:
congenital heart block (CHB). CHB is the result of the
passive transfer of maternal autoantibodies to the fetus
in the presence of genetic predisposing factors that allow
antibody-mediated cardiac damage [91].
A recent study conducted in Sweden found out that a
greater proportion of children with CHB were born dur-
ing the summer [92]. This means that the gestational
period of enhanced CHB susceptibility (18 to 24 weeks
of gestation) occurred during January to March, which is
the time of the year when vitamin D levels were at their
lowest. The authors concluded that the seasonal timing
of the pregnancy may be critical to the onset of CHB
and that vitamin D could be a possible mediator of such
seasonal variation.
Aside from the severe complication of CHB, the pres-
ence of anti-Ro and anti-La antibodies does not seem to
affect the gestational outcome as compared with preg-
nant women with autoimmune diseases negative for
anti-Ro and anti-La. In a large case–control study, no
difference was found in terms of pregnancy loss, intra-
uterine fetal deaths, preterm delivery and small-for-ges-
tational-age infants [93]. However, when compared toage-matched healthy pregnant women, mothers with SS
seem to give birth to offspring of lower birthweight and
a normal delivery is less common.
Patients with SS can also suffer from gynecological
problems more often than healthy women. Vaginal dry-
ness and dyspareunia affect more than half of patients,
with a significant difference with age-matched normal
controls [94-96]. In addition, kissing can be difficult
and unpleasant due to dry mouth [96]. These problems
could lead to a relevant impairment of sexual function
in women with SS [96].
The female dominance and the late onset (40 to 50 -
years of age) in SS can be explained by the regulatory
role of sex hormones [97]. Estrogens seem to protect
secretory glandular acinar cells against apoptosis while
the lack of estrogens during menopause specifically leads
to increased apoptosis of the exocrine cells. Conversely,
the male hormone (testosterone) is converted in exo-
crine glands to dihydrotestosterone (DHT), which is
antiapoptotic and protects against acinar cell apoptosis.
Estrogen-deficient women need to produce dehydroepi-
androsterone (DHEA) in the adrenal glands and convert
it to DHT in the exocrine glands through complex en-
zymatic mechanisms. In SS, such machinery is deranged
so that hormonal changes, in part systemic endocrine
but predominantly local intracrine, contribute to ab-
normal apoptosis of secretory acinar cells. The clear-
ance of this overload of apoptotic material may lead to
the breakdown of autotolerance in immunogenetically
predisposed individuals, giving rise to the complex
pathogenic mechanisms of SS.The therapeutic challenge: old and new treatments
The therapeutic management of pSS is based on symp-
tomatic treatment of glandular manifestations and on
the use of disease-modifying drugs for systemic involve-
ment [98]. Symptomatic treatment with saliva substi-
tutes and eye drops is effective in the relief of sicca
syndrome complaints, whereas immunomodulatory and
immunosuppressive agents are used in patients with severe
extraglandular manifestations and should be tailored to
the specific organ involved. The aim of disease-modifying
drugs is to restore the deregulated immunological path-
ways that are accountable for the disease process.Symptomatic treatment
Symptomatic treatment not only has beneficial effects
on oral and ocular dryness, but can also prevent compli-
cations of sicca syndrome. In fact, untreated severe dry
eye can result in corneal ulceration, vascularization,
opacification and perforation, whereas dry mouth can be
complicated by dental caries, oral candidiasis, and peri-
odontal disease.
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Dry mouth topical treatment encompasses the following
approaches: (a) non-pharmacological measures including
adequate hydration, avoidance of irritants (coffee, alco-
hol, nicotine, and so on), substitution or reduction of
xerostomizing drugs, meticulous oral hygiene (fluoride
application, frequent dental examinations, prompt treat-
ment of candidal infections), and sugar-free gums, loz-
enges and maltose lozenges to increase salivary flow;
(b) saliva substitutes (mucin, caboxymethycellulose,
hydroxymethilcellulose) available in the following forms:
lubricating gels, mouthwashes, lozenges, toothpastes,
intraoral long-release inserts and mucin spray.
A recent Cochrane review of 36 randomized con-
trolled trials (RCTs), involving 1,597 subjects, analyzed
the effect of different saliva stimulants and substitutes
including lozenges, sprays, mouth rinses, gels, oils,
chewing gum or toothpastes, and concluded that there is
no strong evidence that any topical therapy is effective
for relieving the symptoms of dry mouth [99].
The effect of saliva substitutes on patients with SS was
evaluated in four RCTs, enrolling a low number of pa-
tients and using a short-term follow-up [98]. Three out
of four RCTs showed an effectiveness of saliva substi-
tutes in relieving dry symptoms, but they did not ob-
serve any increase in salivary flow.
Dry eye topical treatment
Dry eye topical treatment approach is based on [100]: (a)
non-pharmacologic measures, including avoidance of
dry, smoky, windy environments, prolonged reading,
computer use, use of humidifiers, goggles with side
seals/moisture chambers, avoidance of aggravating drugs
(diuretics, beta blockers, tricyclic antidepressants, anti-
histamines), and punctual occlusion in refractory cases
(plugs, cauterization, surgery); (b) replacement of tear
volume, that is, artificial tears (preservative-free prod-
ucts, hypotonic solutions, and emulsions), autologous
serum eye drops and platelet releasate, which are prom-
ising treatments especially for patients intolerant to arti-
ficial tears or with refractory KCS (the major limitation
to a widespread use of these products is related to their
preparation and preservation); (c) topical drugs counting
ciclosporin A, which was approved for the treatment
of dry eye by the US Food and Drug administration
(FDA) but not by the European Medicine Agency
(EMA), corticosteroids, and non-steroidal anti-inflammatory
drugs (NSAIDs).
There are few rigorous studies on the effect of topical
medications for eyes in patients with SS. As far as artifi-
cial teardrops are concerned, emulsions containing hya-
luronate and hydroxypropylmethyl-cellulose, hypotonic
solutions that decrease the tear film osmolality, and
preservative-free products that are less irritating whenapplied chronically on a daily basis, seem to be the best
options [98].
In patients with severe KCS, topical NSAIDs can be ef-
fective in relieving ocular pain, but they should only be
used for a short time and under medical supervision
since they reduce corneal sensitivity, predisposing users
to corneal damage.
Patients with severe dryness and refractory KCS
may also require topical corticosteroid treatment. Al-
though glucocorticoids exert a rapid and intense anti-
inflammatory effect, they should only be used for a short
time since they can induce severe side effects such as glau-
coma and cataracts.
A number of studies were carried out with the use of
topical ciclosporin A in patients with KCS and SS, show-
ing good results in terms of dry symptom relief and
tear production.
Systemic drugs for sicca symptoms
Secretagogues are indicated in patients with moderate or
severe SS who have dryness and residual esocrinal gland
function [100]. Muscarinic receptor agonists, that is, pilo-
carpine and cevimeline, have been used for both dry
mouth and dry eye and data from RCTs demonstrated a
substantial benefit on sicca symptoms, and improvements
in salivary flow rate and ocular tests results. Cevimeline
was approved for the treatment of dry mouth and dry eye
by the FDA but not by the EMA. The most frequent side
effects of muscarinic receptor agonist therapy are sweat-
ing, increased urinary frequency, and flushing. Mucolytic
agents, that is bromhexine or N-acetylcysteine, have been
used for dry mouth although evidence of their efficacy
is lacking.
Disease-modifying drugs
All the drugs currently used in the treatment of auto-
immune rheumatic diseases have also been administered
to patients with pSS in order to improve sicca symptoms
and modify the immune inflammatory pathways in-
volved in disease progression [98]. Unfortunately, evi-
dence supporting the use of these agents is limited.
Corticosteroids
There are too few studies on oral corticosteroid treat-
ment in patients with SS to draw definitive conclusions.
Corticosteroids at high dosage downregulate the im-
mune inflammatory process within the salivary and lacri-
mal glands [101], but there is no evidence that they
increase salivary and lacrimal flow rates. In addition, the
chronic use of corticosteroids at high dosage should be
avoided in order to prevent severe side effects. Thus,
corticosteroids are currently used primarily in patients
with extraglandular manifestations or in cases with par-
otid swelling.
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Antimalarial agents have been shown to improve sicca fea-
tures and constitutional symptoms such as fatigue and
arthromyalgia [102,103]. Moreover, hydroxychloroquine
has been reported to increase salivary flow rate by
inhibiting glandular cholinesterase [104], decrease inflam-
matory indices, that is, ESR and C reactive protein (CRP),
and immunological abnormalities, that is, γ-globulin, IgG,
IgM, RF, anti-Ro, anti-La. Notably, a decrease of B cell ac-
tivating factor (BAFF) in the tear fluid of patients using
hydroxychloroquine has recently been reported [103].
Importantly, hydroxychloroquine has recently been
shown to exhibit antineoplastic properties. In fact, it
seems to prevent mutations in cells with high mitotic
rate as well as to increase cellular mechanisms of DNA
protection and repair [105]. This is an interesting finding
since patients with pSS have a significantly higher risk of
developing lymphoma than the general population.
Immunosuppressants
Immunosuppressant agents as ciclosporin A, azathio-
prine, methotrexate, mycophenolic acid and leflunomide
are all used empirically in SS. Indeed, only a few studies
including a low number of patients and using a short-
term follow-up (6 months) have been published; there-
fore, their conclusions have a low level of evidence. A
benefit on sicca symptoms without significant improve-
ment in objective tests has been reported by some of
them. These drugs are currently used in the treatment of
extraglandular manifestations and tailored to the organ
specific involvement [106].
Biological drugs
No biologic drugs are currently approved for pSS. How-
ever, some published studies have analyzed the off-label
therapeutic potential of the following biological agents in
pSS: tumor necrosis factor (TNF)α antagonists (etanercept
and infliximab), anti-CD20 and anti-CD22 monoclonal
antibodies (mAbs).
After three open-label studies in which anti-TNFα agents
were shown to improve glandular and extraglandular mani-
festations, two RCTs failed to demonstrate the superiority
of infliximab and etanercept over placebo [107]. Since then,
no further studies with the use of these agents have been
carried out. Notably, increased type I interferon (IFN)-path-
way activation and elevated BAFF serum levels in patients
with SS treated with etanercept have been shown [108].
Since type I IFN and BAFF seem to be involved in the
pathogenesis of SS as well as of other autoimmune diseases
[42], anti-TNFα agents should be avoided in patients with
autoimmune diseases, including SS.
A number of uncontrolled studies and two RCTs have
been published on anti-CD20 treatment (rituximab) in
patients with SS (Table 2) [109-120]. In uncontrolledstudies, rituximab was found to be effective in control-
ling extraglandular manifestations of the disease includ-
ing arthritis, skin vasculitis, particularly when associated
with cryoglobulins, fatigue, and quality of life; however,
only a modest effect on sicca features was demon-
strated [121].
In a recently published RCT, 20 patients affected with
active primary SS and residual salivary gland function
were treated with rituximab and compared to 10 pa-
tients on placebo [119]. In comparison with baseline
values, rituximab treatment significantly improved the
stimulated whole saliva flow rate and several other vari-
ables including B cell number, RF levels, unstimulated
whole saliva flow rate, lacrimal gland function, fatigue,
quality of life, and sicca symptoms. Interestingly, the
drug effect lasted 24 weeks and stimulated whole saliva
flow rate declined when CD20+ B cells started to re-
populate. Despite these promising results, it has been re-
cently shown that rituximab treatment does not alter the
characteristic features of increased clonal expansions
seen in the parotid salivary glands of patients with pSS
[122]. The presence of clonally related immunoglobulin
producing cells before and after rituximab treatment
strongly suggests that immunoglobulin-producing cells
persist in the salivary glands of patients with pSS despite
B cell depletion, which can account for disease relapse
after treatment [122].
Anti-CD22 mAb (4 infusions of 360 mg/m2 of
epratuzumab once every 2 weeks) was administered to
16 patients with SS in an open-label, phase I/II study,
with 6 months of follow-up [123]. A substantial number
of patients achieved a significant clinical response based
on a composite endpoint and the drug was well toler-
ated. Epratuzumab acts through a downregulation of
CD22, which is overexpressed in the peripheral B cells
of patients with SS. According to these preliminary find-
ings, epratuzumab seems to be a promising treatment in
patients with SS.
Conclusions
SS is rather far from being considered a simple disease
of ‘dry mouth and dry eyes’. Research on SS is extremely
active and aims at improving the classification of pa-
tients through more objective criteria (for example, the
2012 SICCA Criteria), probing deeper into the etiology
and the complex pathogenesis of the disease and provid-
ing evidence for the use of new targeted treatments,
such as anti-B cell drugs. The role of infections in the
emergence of SS has been recently addressed, showing
that some infectious agents may promote the disease,
while others may have a protective action against the de-
velopment of autoimmunity. Extraglandular manifesta-
tions are still a challenge in the management of SS,
among which the most serious is B cell NH lymphoma.










1 Case report Marginal zone lymphoma,
xerophthalmia, xerostomia
Improvement in corneal staining,
Schirmer’s test, salivary flow rate,




















6 Retrospective 2 MALT lymphomas, 2 vasculitis
with cryoglobulinemia, 2 parotid
gland enlargement and articular
involvement
Improvement in parotid swelling,
subjective dryness, fatigue and
vasculitis in 5 out of 6 patients




15 Open label 8 early primary SS and 7 MALT
lymphoma: 8 parotid gland swelling,
8 Raynaud’s phenomenon, 13
fatigue, 11 arthralgia, 2 pulmonary
involvement, 2 vasculitis
Remission of lymphoma in 3 of 7
patients, disease stability in 3 of 7,
progression in 1. Increased salivary
secretion, improvement in the rose
Bengal score and tear, BUT, mouth
dryness, arthralgia. No improvement
on Schirmer test.




1 Case report Distal renal tubular acidosis,
xerostomia with mouth
ulcerations
Xerostomia improvement No AE reported
Seror et al.,
2007 [114]
16 Retrospective 5 lymphoma, 2 pulmonary




Remission of lymphoma in 4 of 5
patients; improvement of systemic
involvements in 9 of 11, subjective
dryness in 5 of 16, and regression of
keratitis in 2 of 11. No response on
salivary flow and Schirmer test.





16 Open label Sicca symptoms, pain, fatigue; 1
pulmonary involvement
Improvement in subjective fatigue,
pain, dryness, and pulmonary
involvement. No changes in
unstimulated salivary flow, salivary
gland score and ophthalmologist
evaluation.




8 (PL 9) RCT Fatigue, ocular and mouth dryness;
no systemic involvement
Improvement in fatigue, general
health and SF-36. No improvement
on Schirmer test and salivary flow
rate.
2 infusion reactions, 1 delayed




8 Open label Severe glandular and
musculoskeletal involvement,
cutaneous vasculitis
Improvement in parotid swelling,
articular involvement, fatigue, and
subjective dryness in 4 of 7 patients









Complete response in 67% of
patients, partial response in 20%,
no response in 13%










6 vasculitis, thyroid dysfunction
Improvement in saliva flow rate,
stimulated lacrimal gland function;
but not in BUT and Schirmer test.
Improvement in SF-36 and MFI.
Improvement in extraglandular
manifestations.
1 serum sickness, 12 infections
in 11 patients on rituximab vs





17 Registry All peripheral nervous system
involvement: 10 patients with
cryoglobulinemia and/or vasculitis,
7 patients without cryoglobulinemia
and/or vasculitis
Response in 9 of 10 patients with
cryoglobulinemia and/or vasculitis,
and in 2 of 7 without
cryoglobulinemia and/or vasculitis





AE, adverse event; BUT, break-up time; CMV, cytomegalovirus; MALT, mucose-associated lymphoid tissue; MFI, multidimensional fatigue inventory; PL, placebo;
RCT, randomized controlled trial; SF-36, Short Form 36 Health Survey.
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lymphoma and peripheral neuropathy are associated
with low vitamin D levels opens new avenues in the un-
derstanding of the disease and in its treatment. The fact
that CHB is also more frequent during winter and asso-
ciates with hypovitaminosis D supports the idea that
the role of vitamin D should be further investigated in
SS and adequate supplementation should be given to
these patients.
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